Genevac speeds up lab-scale freeze-drying
Genevac has introduced new technology for its Model HT-4X centrifugal evaporator whereby the system can be used to accelerate lyophilisation of water and water mixtures by as much as three hundred per cent.
Archives for May 15, 2005
NanoInk seeks pack-level partners
US nanotechnology company NanoInk has said it wants to forge partnerships with packaging companies to develop a layered brand protection solution for pharmaceutical customers.
Qiagen enter DNA methylation collaboration
Qiagen and Epigenomics have entered into a collaboration to jointly develop and introduce preanalytical solutions for DNA methylation analysis to focus on in-vitro diagnosis (IVD) and pharmacogenomics markets.
Agilent opens Shanghai science training centre
Agilent Technologies is to open a new Life Sciences and Chemical Analysis (LSCA) technical training centre in Shanghai in a move that reflects the current trend for biotech companies to divert resources to offshoring operations.
InterMune presents encouraging HCV drug data
Intermune has announced the results of preclinical data on the specificity and tolerability of two potent and selective small molecule inhibitors of the hepatitis C virus (HCV). The findings are significant, as they have previously been shown to be...
Applied Bio named top mass spec supplier
According to a new report, Applied Biosystems/MDS Sciex is the leading mass spectrometer brand in all regions and market segments. Suppliers in this market will benefit from the 19 per cent of mass spectrometer users surveyed who plan to purchase a...
Biomarker indicates patient susceptibility to treatment
According to a latest study, which revealed the presence of a unique genetic biomarker, the quality of life for patients undergoing treatment for colorectal cancer may be significantly improved, potentially minimising the unwanted side effects.
Pliva exits branded drug business
Croatian pharmaceutical company Pliva has decided to opt out of the proprietary medicines business and refocus its business on the generics and active pharmaceutical ingredients sectors, reports Phil Taylor.
Vaccine decline must be halted, says opinion leader
During the past 50 years, the number of pharmaceutical companies making vaccines has decreased dramatically, and those that still make them have reduced resources to produce new ones, writes Phil Taylor.